Dr. Lindsey's Multiple Sclerosis Website

Tecfidera update September, 2016

Home
ACTRIMS Forum 2017
ECTRIMS 2016
Tecfidera update September, 2016
ECTRIMS 2015
AAN 2015
ACTRIMS-ECTRIMS 2014
AAN 2014
Current Treatments (updated 7/7/13)
Gilenya (updated 4/20/2012)
Tysabri and PML
Ampyra
Recent and current research
Old meetings
New diagnosis of MS
Multiple Sclerosis Basic Information
Interferon versus Glatiramer--update 11/07
Talk on stem cells--2/13/08
About Dr. Lindsey
Research Interests
Map/Directions
Links
Clinic information
Contact Us

PML with tecfidera

There have now been 4 cases of PML in patients on tecfidera for MS. I don't have complete details on all the cases.  I do know that the first case reported had a very low white blood cell count for years before developing PML.  One of the recent cases had a normal white cell count at all the screening tests before they developed PML.  I don't have details on the other cases.   
PML is a brain infection caused by the JC virus.  This virus infects over half of people, and stays in the body lifelong after infection.  The JC virus is normally harmless, but in people that are immunosuppressed, it can cause PML.  PML has been a significant issue in MS patients treated with Tysabri, and there have also been rare cases of PML with Gilenya.  
When Tecfidera first came on the market, there had been 4 cases of PML reported in people with psoriasis treated with a similar drug.  So the  possibility of PML has been a concern.  But the previous cases were all in people who had been treated with other drugs that strongly suppress the immune system.  
I have a number of patients on Tecfidera, but I would not recommend changing treatment for now.  I am carefully following white cell counts and also the total lymphocyte count.  I have switched treatment in a few people with a persistently low count.  
This looks like a rare problem, but not completely avoidable.  I will continue to check white cell and lymphocyte counts in the blood at every visit for my patients on tecfidera, and will keep discussing the risks at each clinic visit.     

J. William Lindsey, MD
University of Texas Multiple Sclerosis Research Group
Houston, Texas

copyright 2007-2017 John William Lindsey